Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (695)	10/29/1999 8:22:00 AM
From: Dr. John M. de Castro	Respond to of 1494

Excellent if not unexpected news. This is great news. But, you have to read between the lines a bit. Merz wants to reveal the results at a scientific meeting. This is very appropriate. However, NTII wants the results public before April 2000. Thus, NTII put out the press release, with, I'm sure, Merz' approval. The wording is careful not to provide the actual results. But, the statement "the initial results look promising" is very revealing. NTII would not have said this without Merz' approval. NTII would also leave themselves open to law suits for making a statement like this unless they could back it up. Hence, IMHO, this is NTII's way of letting the world know that Merz has demonstrated statistically significant cognitive improvements in demented patients with memantine. This is very significant, as this is the endpoint that the FDA favors in looking at memantine for approval. This is a major step forward for NTII-Merz. It once again demonstrates the safety and efficacy of memantine as a neuroprotectant. It bodes well for the December release of the Neuropathic Pain results. Best regards John de C

To: JMarcus who wrote (695)	11/1/1999 2:19:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1494

Hi JMarcus, Clearly there is still significant accumulation ongoing. This could be related to the news release last Thursday. I would guess it is more likely in anticipation of an even greater event which has a high near term probability. This accumulation has been ongoing with little selloff relative to Thursdays news. With accumulation up through $2 today on relatively low volume I would guess the post release valuation would place the stocks shareprice above three. Recall that Neuroinvestments price projection was/is? above $5 if all potential near-term events play out faviorably... This will take FDA acceptance of both trial results and a significant collaboration. Either way the recent accumulation suggests we are headed in the right direction... BEST WISHES Jeffrey